Cross-Cutting Engineering

Stability and Accelerated Aging

Evaluate product, formulation, package, and device performance drift under controlled conditions to support shelf-life and change-control decisions.

We run accelerated and real-time conditioning with scheduled pulls, chamber records, and paired performance or chemistry readouts to quantify trends.

ISO 17025ICH Q1A (R2)USP <659>FDA stability guidanceReviewed 2026-05-16
Request a quoteSubmit a sample

Purpose & when to use

Stability and accelerated aging study support uses environmental chambers, scheduled pull points, and paired performance or analytical readouts to measure drift in products, formulations, devices, and packages. Programs can align to ICH Q1A (R2), USP <659>, and FDA stability guidance while preserving ISO 17025 traceability for sample identity, chamber records, method controls, and reported uncertainty:

  1. ICH Q1A (R2) accelerated programs for inhalation products using environmental chambers and PSD or emitted-dose pulls to estimate early shelf-life risk.
  2. FDA stability guidance real-time programs for nasal sprays, aerosols, or devices using chamber storage and periodic performance or chemistry readouts.
  3. USP <659> storage-condition selection for packaged products using temperature/RH chambers, excursion logs, and defined pull schedules.
  4. ICH Q1B photo-stability or material-aging screens using UV exposure, retained samples, and paired chemistry or appearance checks.
  5. USP <1118> transport-stress linkage for packaged devices using cyclic abuse profiles, post-stress storage, and acceptance criteria.

Use stability and accelerated aging support when time, storage condition, material change, or shipping exposure could alter performance. The method plan defines conditions, pull timing, paired tests, and the evidence needed for shelf-life or design-change decisions.

Built for products, packages, and device programs

Stability programs cross pharmaceutical, device, packaging, and consumer-product boundaries. The same controlled-condition framework can support ICH, USP, FDA, and product-specific acceptance criteria.

  • Inhalation productsMDI, DPI, nebulizer programs
  • Nasal spraysPump and unit-dose formats
  • Consumer aerosolsSprays, valves, packages
  • Medical devicesMaterials and performance attributes
  • PackagingConfigurations and storage protection

Instrumentation & measurement ranges

Conditioning and readout platforms are chosen per protocol, with storage state, pull schedule, and paired test methods documented before the study starts.

25 - 40 Cstorage

Environmental chambers (temperature/RH)

Controlled storage for real-time, intermediate, and accelerated programs with condition logging, chamber verification, and documented excursion handling.

20 - 60 Cexcursion

Cyclic stress and abuse protocols

Temperature cycling, humidity stress, and fit-for-purpose excursions used when shipping, distribution, or expected-use conditions may drive performance drift.

1 - 2 kLuxexposure

UV exposure for photo-stability

Optional light exposure for ICH Q1B-style photo-stability or material-aging questions when the product, package, or formulation has light sensitivity risk.

0 - 12 motrend

Paired performance and chemistry readouts

PSD, emitted dose, plume, VOC/by-product, HPLC assay, impurity, appearance, or package checks coordinated at defined pulls.

Test method options

MethodStrengthsTradeoffAligned with
Accelerated aging program (environmental chambers)
  • Faster drift signal from elevated temperature/RH conditions aligned to ICH Q1A (R2) and FDA stability guidance.
  • Supports early shelf-life estimates, formulation screens, and packaging comparisons before real-time data mature.
Requires documented acceleration assumptions, endpoint limits, and bounds for extrapolation.
ICH Q1A (R2)FDA stability guidance
Real-time stability program (scheduled pulls)
  • Most representative evidence for storage claims under ICH Q1A (R2), USP <659>, and FDA stability guidance.
  • Pull calendars, retains, chamber logs, and paired readouts create a traceable long-term record.
Decision timing is slower, so sample allocation and pull logistics must be disciplined.
ICH Q1A (R2)USP <659>FDA stability guidance
Photo-stability and material-aging screen (UV exposure)
  • Targets light-driven appearance, assay, impurity, or material changes under ICH Q1B / Q1C exposure framing.
  • Pairs exposed and protected samples so packaging protection or formulation sensitivity is visible.
Light exposure does not replace temperature/RH stability unless the protocol states that limited question.
ICH Q1B / Q1C
Transport stress linkage (cyclic abuse profiles)
  • Connects distribution excursions to post-stress performance under USP <1118> and product-specific acceptance criteria.
  • Useful for package changes, device revisions, and shipping-lane questions before full real-time data arrive.
Requires a defined stress profile and acceptance criteria before samples enter conditioning.
USP <1118>
Performance-plus-chemistry trending (paired readouts)
  • Links physical performance drift to assay, impurity, VOC, or by-product changes across pull points.
  • Supports ICH Q1B / Q1C package or container questions when configuration changes may affect stability.
Coordinated sampling increases method-control needs across storage, performance, and chemistry teams.
ICH Q1B / Q1C

Setup configurations

A stability study starts with a written protocol that fixes storage conditions, package configuration, pull timing, sample allocation, acceptance criteria, and readout methods. The setup below keeps the storage record connected to the tests performed at each pull, so trend interpretation is tied to known sample history.

Environmental controls

Temperature/RH targets, chamber assignment, condition logging, calibration checks, and excursion review plan.

Sample numbers

Pull schedule, retain allocation, replicate count, destructive-test needs, and replacement rules for missed pulls.

Sample matrix

Formulation, device revision, packaging configuration, orientation, and storage state documented before conditioning.

Exposure profile

Accelerated, real-time, photo-stability, transport, or cyclic-stress profile selected for the decision under study.

Chain of custody

Receipt, storage transfer, pull execution, readout handoff, and final disposition recorded for each sample group.

Quality anchors for stability evidence

Stability programs need clear regulatory posture before the first sample enters storage. These anchors define how conditions, pull records, acceptance criteria, and reporting are framed.

  • ISO 17025AccreditedTesting-laboratory competence, traceable records, and method control.
  • ICH Q1A (R2)AlignedStability condition selection, pull timing, and shelf-life evidence.
  • USP <659>AlignedPackaging and storage condition terminology for articles.
  • FDA stability guidanceAlignedSubmission-facing stability expectations and documented rationale.

Key data outputs & reporting

Every stability program delivers condition history, pull-point results, and trend interpretation in a format the customer can use for shelf-life, storage, design-change, or shipping decisions. Reports state the protocol, assumptions, acceptance criteria, chamber events, paired test methods, and uncertainty contributors, then organize the data by time, condition, lot, package, device revision, endpoint, and acceptance outcome.

Primary outputs

  • Trend tables for key performance attributes such as PSD, emitted dose, plume, appearance, VOCs, assay, or impurities.
  • Condition history, chamber excursions, pull execution records, and sample identity checks tied to each result set.
  • Shelf-life, re-test interval, or design-change discussion with assumptions, limits, and observed drift rates stated.

Deliverables

#FormatContents
01PDF reportProtocol, conditions, controls, results, trend interpretation, and stated assumptions.
02CSV / XLSX datasetsPull-point results, chamber logs, trend tables, and calculated deltas.
03FiguresTrend plots, overlays, excursion summaries, and condition comparisons.
Extended deliverables · multi-arm comparability · stability · predicate studies
  • Shelf-life appendix — Drift rates, confidence intervals, and shelf-life or re-test interval rationale.
  • Change-control pack — Side-by-side trends for package, material, formulation, or device revisions.
  • Transport linkage summary — Stress profile, post-stress checks, and comparison to unstressed retains.

QA / QC & data integrity

Stability data are only useful when the storage state and pull history are defensible. QA / QC controls therefore cover chamber readiness, sample identity, pull execution, paired method controls, and exception handling from receipt through final reporting. The study file preserves both the trend data and the conditions that produced them.

Chamber calibration, verification, and continuous condition logs reviewed against the protocol.

Pull-point checklists, sample identity verification, and chain-of-custody records for every sample group.

Method QC for paired readouts, including controls, calibration checks, blanks, repeats, or recovery checks as applicable.

Defined acceptance criteria for chamber excursions, outliers, missed pulls, and trend flags.

Storage configuration photos or diagrams when orientation, package state, or device setup affects interpretation.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)
17025Accredited testing
900+Studies Performed
17+Years in operation
300+Clients supported

Common questions

Stability questions usually come from product, quality, regulatory, packaging, and device teams deciding how much time-based evidence they need before a claim, submission, or change-control decision. These answers cover accelerated versus real-time programs, condition selection, pull-point testing, transport stress, and deliverables. Reach out if your product, package, or regulatory frame needs a different study structure.

Q.Which is better, accelerated aging or real-time stability?
A.They answer different questions. Accelerated aging gives earlier drift signals and risk estimates. Real-time stability provides representative long-term evidence. Many programs use both, with assumptions and limits stated in the protocol and report.
Q.Can performance tests run at each pull?
A.Yes. Pulls can pair with PSD, emitted dose, plume, VOC/by-product, appearance, assay, impurity, or package checks. We define the readout list before storage so sample counts and timing match the decision.
Q.How are conditions and pull points chosen?
A.We start from ICH, USP, FDA, or product-specific frames, then adjust for product risk, expected drift, package configuration, and decision timing. The protocol records conditions, pull dates, acceptance criteria, and excursion handling.
Q.Do you include shipping or transport stress?
A.Yes. Transport profiles can be added before storage or used as a separate stress leg. Post-stress performance is compared with unstressed retains when the program needs distribution-risk evidence.
Q.What do stability deliverables include?
A.Deliverables usually include a PDF report, CSV or XLSX datasets, trend plots, chamber logs, pull records, and discussion of drift, uncertainty, and assumptions. Change-control or shelf-life appendices can be added.

Standards & guidance

Stability and accelerated aging studies are scoped around the product, decision, and regulatory frame. ARE Labs treats ISO 17025 as the quality-system anchor for traceable testing and aligns study design to ICH, USP, and FDA stability guidance where applicable. The cards below identify the standards most often used for storage conditions, photo-stability, packaging, and transport-linked evidence.

QA & Regulatory - Accredited

ISO 17025

Testing-laboratory competence, traceable records, calibration control, and uncertainty contributorsView standard ->Stability & Shelf Life - Aligned

ICH Q1A (R2)

Stability testing of new drug substances and products, including condition selection and pull timingView standard ->Stability & Shelf Life - Aligned

ICH Q1B / Q1C

Photo-stability and package-configuration stability considerations for light-sensitive or changed productsView standard ->Pharmacopeial - Aligned

USP <659>

Packaging and storage requirements terminology for articles and labeled storage conditionsView standard ->Pharmacopeial - Aligned

USP <1118>

Monitoring and interpreting distribution, storage, and transport conditions for pharmaceutical articlesView standard ->QA & Regulatory - Aligned

FDA stability guidance

FDA expectations for stability evidence, storage claims, and submission-facing documentationView standard ->

Related services & devices

Service

Dose Uniformity & Emitted Dose

Pairs with stability pulls when per-actuation dose or shot-to-shot variability may drift during storage.Read more ->Devices

Drug Delivery

Inhalation, nasal, and oral delivery devices often need stability evidence across formulation, actuator, or package changes.Read more ->Service

Particle Size Distribution (PSD) Testing

PSD trending can show aerosol performance drift at stability pulls for inhalation, nasal, and spray products.Read more ->Devices

Spray & Aerosol

Consumer sprays and aerosol packages use aging studies to evaluate valve, material, emission, or package drift.Read more ->